CRISPR-HOLMES-based NAD+ detection
Frontiers in Bioengineering and Biotechnology · 25.03.2024 · 12
DOI: 10.3389/fbioe.2024.1355640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 25.03.2024. Verfasst von Songkuan Zhuang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultr…. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Studies have indicated that the intracellular nicotinamide adenine dinucleotide (NAD + ) level is associated with the occurrence and development of many diseases. However, traditional nicotinamide adenine dinucleotide (NAD + ) detection techniques are time-consuming and may require large and expensive instruments. We recently found that the clustered regularly interspaced short palindromic repeat (CRISPR)-Cas12a protein can be inactivated by AcrVA5-mediated acetylation and reactivated by CobB, using NAD + as the co-factor. Therefore, in this study, we created a CRISPR-Cas12a-based one-step HOLMES(NAD + ) system for rapid and convenient NAD + detection with the employment of both acetylated Cas12a and CobB. In HOLMES(NAD + ), acetylated Cas12a loses its trans -cleavage activities and can be reactivated by CobB in the presence of NAD + , cutting ssDNA reporters to generate fluorescence signals. HOLMES(NAD + ) shows both sensitivity and specificity in NAD + detection and can be used for quantitative determination of intracellular NAD + concentrations. Therefore, HOLMES(NAD + ) not only provides a convenient and rapid approach for target NAD + quantitation but also expands the application scenarios of HOLMES to non-nucleic acid detection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Shenzhen University Medical…
- Department of Clinical Laboratory, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
- Shenzhen Bao An Peoples Hospital, Shenzhen, China.
- Department of Clinical Laboratory, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, National Clinical Research Center for Infectious Di…
- Institute of Antibiotics, Huashan Hospital, Fudan University & Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission, Shanghai, China.
- Shanghai Tolo Biotechnology Co Ltd, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Zhuang, S., Hu, T., Zhou, H., He, S., Li, J., Zhang, Y., Gu, D., Xu, Y., Chen, Y., & Wang, J. (2024). CRISPR-HOLMES-based NAD+ detection. Frontiers in Bioengineering and Biotechnology, 12. https://doi.org/10.3389/fbioe.2024.1355640
Vancouver
Zhuang S, Hu T, Zhou H, He S, Li J, Zhang Y, et al. CRISPR-HOLMES-based NAD+ detection. Frontiers in Bioengineering and Biotechnology. 2024;12. doi:10.3389/fbioe.2024.1355640
BibTeX
@article{Zhuang2024,
author = {Zhuang, Songkuan and Hu, Tianshuai and Zhou, Hongzhong and He, Shiping and Li, Jie and Zhang, Yuehui and Gu, Dayong and Xu, Yong and Chen, Yijian and Wang, Jin},
title = {CRISPR-HOLMES-based NAD+ detection},
journal = {Frontiers in Bioengineering and Biotechnology},
year = {2024},
volume = {12},
doi = {10.3389/fbioe.2024.1355640}
}
EUVIMED